



September 15, 2010

PDL BioPharma to Present at Upcoming Investor Conferences

INCLINE VILLAGE, Nev., Sept 15, 2010 /PRNewswire via COMTEX/ --

PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the following upcoming conferences.

UBS Global Life Sciences Conference

Tuesday, September 21, 2010

2:30 p.m. ET

New York City

5th Annual JMP Securities Healthcare Conference

Monday, September 27, 2010

9:00 a.m. ET

New York City

To access the live and subsequently archived webcasts of the presentations, go to the Company's website at <http://www.pdl.com> and go to "Company Presentations & Events." Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary. The archived webcast will be available for seven days following each presentation.

About PDL BioPharma

PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The Company receives royalties on sales of a number of humanized antibody products marketed today based on patents which expire in late 2014. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

SOURCE PDL BioPharma, Inc.